Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
Make-or-break FDA adcoms beckon for two antibiotics.
New data for heart failure pill could clear the way for use in less severely ill patients.
The companies hope that the US regulator approves patisiran and lorlatinib.
Progenics hopes to secure US approval for Azedra, while Allergy Therapeutics awaits phase III data with its birch vaccine.
Two weeks ago BAN2401 was hailed as a possible disease-modifying Alzheimer's drug. Full data at the AAIC meeting to will show whether or not this is was all hype.
Amarin's huge cardiovascular outcomes study of Vascepa will read out soon, but an emphatic victory looks unlikely.
Pivotal data on Astrazeneca’s lupus project anifrolumab are due, while Astellas and Pfizer await a US approval decision on Xtandi.
Updated results of Spark's haemophilia A gene therapy are due this quarter, and could help the company claw back ground from its rival Biomarin.